Business UpdateApr 27, 2026, 05:17 PM
LXEO to Present New Data on Gene Therapy Programs & AAV Manufacturing at ASGCT
AI Summary
Lexeo Therapeutics, Inc. announced it will present new data supporting its cardiac gene therapy programs and optimized AAV manufacturing approach at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) from May 11-15, 2026. The presentations will cover encouraging cardiac and neurologic data in Friedreich ataxia (FA), a novel TNNI3 gene therapy program, and an industry-leading AAV manufacturing platform. This reflects the company's continued progress across its pipeline and ability to advance differentiated programs.
Key Highlights
- New data supporting cardiac gene therapy programs to be presented at ASGCT.
- Optimized AAV manufacturing approach data will be highlighted.
- Encouraging cardiac and neurologic data for Friedreich ataxia (FA) gene therapy (LX2006).
- Novel TNNI3 gene therapy program enabled by an innovative porcine disease model.
- Demonstrated comparability between HEK293 and Sf9 Baculovirus AAVrh.10 clinical manufacturing process.
- Scale-up and manufacturing comparability of Sf RVN Baculovirus production process from 10L to 200L for AAV.
- Presentations scheduled for the 29th Annual ASGCT Meeting, May 11-15, 2026.
Price Impact
More from LXEO